All tissues have some capability for synthesis of the non-essential amino acids, amino acid remodeling, and conversion of non-amino acid carbon skeletons into amino acids and other derivatives that contain nitrogen. However, the liver is the major site of nitrogen metabolism in the body. In times of dietary surplus, the potentially toxic nitrogen of amino acids is eliminated via transaminations, deamination, and urea formation; the carbon skeletons are generally conserved as carbohydrate, via gluconeogenesis, or as fatty acid via fatty acid synthesis pathways. In this respect amino acids fall into three categories: glucogenic, ketogenic, or glucogenic and ketogenic. Glucogenic amino acids are those that give rise to a net production of pyruvate or TCA cycle intermediates, such as 2-oxoglutarate (α-ketoglutarate) or oxaloacetate, all of which are precursors to glucose via gluconeogenesis. All amino acids except lysine and leucine are at least partly glucogenic. Lysine and leucine are the only amino acids that are solely ketogenic, giving rise only to acetyl-CoA or acetoacetyl-CoA, neither of which can bring about net glucose production.
A small group of amino acids comprised of isoleucine, phenylalanine, threonine, tryptophan, and tyrosine give rise to both glucose and fatty acid precursors and are thus, characterized as being glucogenic and ketogenic. Finally, it should be recognized that amino acids have a third possible fate. During times of starvation the reduced carbon skeleton is used for energy production, with the result that it is oxidized to CO2 and H2O.back to the top
Dietary amino acids can be consumed as free amino acids or, more often, they are acquired from digested dietary proteins that are hydrolyzed through the concerted actions of gastric and pancreatic peptidases. Dietary protein digestion begins in the stomach via the actions of the pepsins, and continues within the lumen of the duodenum. Within the small intestine there are two principal pancreatic enzymes involved in protein digestion; trypsin and chymotrypsin. Several additional pancreatic peptidases play a lesser role in peptide digestion and include the carboxypeptidases and elastin.
The initial enzyme involved in protein digestion is gastric pepsins. Pepsins are derived from the precursor zymogen, pepsinogen. Pepsins are released from pepsinogen via acid-induced autocatalysis. Pepsins hydrolyze peptide bonds on the C-terminal side of aromatic and hydrophobic amino acids. Approximately 20% of overall protein digestion is accomplished via the actions of pepsins. Due to the acidic pH optimum for the action of pepsins, these enzymes are inhibited when the gastric juice (chyme) passes from the stomach and is mixed with alkaline pancreatic juice in the duodenum.
The remainder of protein digestion occurs within the duodenum and jejunum of the small intestine. Digestion here is primarily the result of the actions of trypsin and chymotrypsin, and to a lesser extent by elastase, and carboxypeptidases A and B, all of which are secreted by the pancreas. Active trypsin is generated via the action of enteropeptidase on pancreatic trypsinogen. Enteropeptidase is an enzyme secreted by cells of the crypts of Lieberkühn and resides in the brush-border membranes of duodenal mucosal cells. Trypsin then cleaves more trypsinogen to trypsin, as well as chymotrypsinogen, proelastase, and procarboxypeptidases to their active forms. Following digestion, free amino acids, as well as peptides (2–6 amino acids in length) are absorbed by enterocytes of the proximal jejunum. Some absorption also occurs in the duodenum and a minor amount in the ileum. Although there is little nutritional significance to whole protein absorption, some undigested dietary protein does get absorbed by colonic mucosal cells.
The absorption of amino acids requires an active transport process that is dependent upon either Na+ or H+ co-transport. There are several amino acid transporters encompassing seven distinct transport systems which are further grouped into three broad categories. There are the neutral amino acid (monoamino monocarboxylic) transporters, the dibasic (and cysteine) amino acid transporters, and the acidic (dicarboxylic) amino acid transporters. All of these transporters are members of the solute carrier (SLC) family of transporters.
Intestinal uptake of peptides involves H+ co-transporters which are also members of the SLC family. The most abundant peptide transporter is PepT1 (SLC15A1) but there are three additional peptide transporters within the SLC15 subfamily. Within intestinal enterocytes the absorbed peptides are hydrolyzed to free amino acids via enterocyte cytoplasmic peptidases. The free amino acids are then transported across the apical membranes of enterocytes and enter the portal circulation.back to the top
Hartnup disorder was first described in 1956 in the Hartnup family in London as a renal aminoaciduria of neutral amino acids associated with a pellagra-like skin rash and episodes of cerebellar ataxia. The disorder is caused by a defect in neutral amino acid transport in the apical brush border membranes of the small intestine and in kidney proximal tubules. The transporter is a member of the solute carrier family, specifically the SLC6A19 transporter. SLC6A19 is also known as the system B(0) neutral amino acid transporter 1 [B(0)AT1]. SLC6A19 is responsible for the transport of neutral amino acids in a Na+-dependent transport reaction. The lack of intestinal tryptophan transport is responsible for most, if not all, clinical phenotypes of Hartnup disorder. The pellagra-like skin rash seen on sun-exposed areas of skin in Hartnup disorder patients is most likely the result of nicotinamide deficiency due to a lack of tryptophan which is a precursor for its synthesis. Symptoms of Hartnup disorder may begin in infancy or early childhood, but sometimes they begin as late as early adulthood. Symptoms may be triggered by sunlight, fever, drugs, or emotional or physical stress. Most symptoms occur sporadically and are caused by a deficiency of niacin. When Hartnup disorder manifests during infancy the symptoms can be variable in clinical presentation. These symptoms include failure to thrive, photosensitivity, intermittent ataxia, nystagmus and tremor. Patients with Hartnup disorder can remain asymptomatic on a high protein diet due to intestinal peptide absorption via the actions of the transporter, PepT1.back to the top
|Nonessential||Alanine, Asparagine, Aspartate, Cysteine, Glutamate, Glutamine, Glycine, Proline, Serine, Tyrosine|
|Essential||Arginine*, Histidine, Isoleucine, Leucine, Lysine, Methionine*, Phenylalanine*, Threonine, Tryptophan, Valine|
*The amino acids arginine, methionine and phenylalanine are considered essential for reasons not directly related to lack of synthesis. Arginine is synthesized by mammalian cells but at a rate that is insufficient to meet the growth needs of the body and the majority that is synthesized is cleaved to form urea. Methionine is required in large amounts to produce cysteine if the latter amino acid is not adequately supplied in the diet. Similarly, phenylalanine is needed in large amounts to form tyrosine if the latter is not adequately supplied in the diet.back to the top
Glutamate is synthesized from its' widely distributed α-keto acid precursor by a simple one-step transamination reaction catalyzed by glutamate dehydrogenase (GDH). As discussed in the Nitrogen Metabolism page, the glutamate dehydrogenase reaction plays a central role in overall nitrogen homeostasis.
Like glutamate, aspartate is synthesized by a simple one-step transamination reaction catalyzed by aspartate aminotransferase, AST (formerly referred to as serum glutamate-oxalate transaminase, SGOT). Humans express two different AST enzymes, both of which function as homodimeric enzymes. One AST enzyme is a cytosolic enzyme and the other is a mitochondrial enzyme. The cytosolic AST enzyme is synthesized by the GOT1 gene (glutamate-oxalate transaminase 1) that is located on chromosome 10q24.1–q25.1 and is composed of 9 exons that encode a 413 amino acid protein. The mitochondrial AST enzyme is synthesized from the GOT2 gene that is located on chromosome 16q21 and is composed of 10 exons that generate two alternatively spliced mRNAs that encode two different isoforms: isoform 1 (430 amino acids) and isoform 2 (387 amino acids).
Aspartate can also be derived from asparagine (whose synthesis is outlined below) through the action of asparaginase. The importance of aspartate as a precursor of ornithine for the urea cycle is described in the Nitrogen Metabolism page. In addition, the use of asparaginase as an anti-cancer therapeutic, for certain types of leukemia, stems from the fact that, although most cells produce all the asparagine they need from the asparagine sythetase reaction, some leukemic cells require exogenous asparagine. These cells acquire the needed exogenous asparagine from the plasma. Chemotherapy using the enzyme asparaginase takes advantage of this property of leukemic cells by hydrolyzing serum asparagine to ammonia and aspartic acid, thus depriving the neoplastic cells of the asparagine that is essential for their characteristic rapid growth. The asparaginase gene (symbol: ASPG) is located on chromosome 14q32.33 and is composed of 19 exons that encode a protein of 573 amino acids.
Aside from its role in protein synthesis, alanine is second only to glutamine in prominence as a circulating amino acid. In this capacity it serves a unique role in the transfer of nitrogen from peripheral tissue to the liver. Alanine is transferred to the circulation by many tissues, but mainly by muscle, in which alanine is formed from pyruvate at a rate proportional to intracellular pyruvate levels. Liver accumulates plasma alanine, reverses the transamination that occurs in muscle, and proportionately increases urea production. The pyruvate is either oxidized or converted to glucose via gluconeogenesis. When alanine transfer from muscle to liver is coupled with glucose transport from liver back to muscle, the process is known as the glucose-alanine cycle. The key feature of the cycle is that in 1 molecule, alanine, peripheral tissue exports pyruvate and ammonia (which are potentially rate-limiting for metabolism) to the liver, where the carbon skeleton is recycled and most nitrogen eliminated.
There are two main pathways to production of muscle alanine: directly from protein degradation, and via the transamination of pyruvate by alanine transaminase, ALT (also referred to as serum glutamate-pyruvate transaminase, SGPT).
The Glucose-Alanine Cycle: The glucose-alanine cycle is used primarily as a mechanism for skeletal muscle to eliminate nitrogen while replenishing its energy supply. Glucose oxidation produces pyruvate which can undergo transamination to alanine. This reaction is catalyzed by alanine transaminase, ALT (ALT used to be called serum glutamate-pyruvate transaminase, SGPT). Additionally, during periods of fasting, skeletal muscle protein is degraded for the energy value of the amino acid carbons and alanine is a major amino acid in protein. The alanine then enters the blood stream and is transported to the liver. Within the liver alanine is converted back to pyruvate which is then a source of carbon atoms for gluconeogenesis. The newly formed glucose can then enter the blood for delivery back to the muscle. The amino group transported from the muscle to the liver in the form of alanine is converted to urea in the urea cycle and excreted.
The sulfur for cysteine synthesis comes from the essential amino acid methionine. A condensation of ATP and methionine, catalyzed by methionine adenosyltransferase (MAT), yields S-adenosylmethionine (SAM or AdoMet). In the production of SAM all phosphates of an ATP are lost: one as Pi and two as PPi. It is adenosine which is transferred to methionine and not AMP. MAT is also called S-adenosylmethionine synthetase. There are three MAT genes in humans identified as MAT1A, MAT2A and MAT2B. The MAT enzymes encoded by the MAT1A gene function as either a homotetramer identified as MAT I (called the alpha form), or as a homodimer identifed as MAT III (called the beta form). The MAT I and MAT III isoforms are only expressed in the liver. The MAT enzyme encoded by the MAT2A gene is identified as MAT II (called the gamma form). The MAT II enzyme is expressed in several non-hepatic tissues. The MAT1A gene is located on chromosome 10q22 and is composed of 10 exons that encode a protein of 395 amino acids. The MAT2A gene is located on chromosome 2p11.2 and is composed of 9 exons that encode a protein of 395 amino acids. The MAT2B gene is located on chromosome 5q34 and is composed of 8 exons that generate two alternatively spliced mRNAs encoding the MAT 2 beta isoform 1 (334 amino acids) and the MAT 2 beta isoform 2 (323 amino acids) enzymes.
SAM serves as a precurosor for severals methyl transfer reactions where the most physiologically significant reaction is the conversion of norepinephrine to epinenephrine (see Specialized Products of Amino Acids). The result of methyl transfer is the conversion of SAM to S-adenosylhomocysteine. Transmethylation reactions employing SAM are extremely important, but in the context of cysteine biosynthesis, the role of S-adenosylmethionine in transmethylation is secondary to the production of homocysteine (essentially a by-product of transmethylase activity).
S-adenosylhomocysteine is then cleaved by adenosylhomocyteinase (also called S-adenosylhomocysteine hydrolase) to yield homocysteine and adenosine. Adenosylhomocysteinase is encoded by the AHCY gene located on chromosome 20q11.22 and is composed of 17 exons that generate two alternatively spliced mRNAs encoding adenosylhomocysteinase isoform 1 (432 amino acids) and adenosylhomocysteinase isoform 2 (404 amino acids).
Homocysteine can be converted back to methionine by methionine synthase (also called homocysteine methyltransferase). This reaction was also discussed in the context of vitamin B12-requiring enzymes in the Vitamins page. The methionine synthase reaction represents the clinically most significant of only two vitamin B12-requiring enzymes in human cells. Methionine synthase, in addition to B12, requires the folate-derived vitamin co-factor, N5-methyltetrahydrofolate (N5-methyl THF). Methionine synthase is encoded by the MTR gene (5-methyltetrahydrofolate-homocysteine methyltransferase) located on chromosome 1q43 and is composed of 34 exons that generate three alternatively spliced mRNAs.
Deficiency in B12, or folate, or defects in the MTR gene all will result in the development of megaloblastic anemias. The anemia develops due to the trapping of folate in the reduced form (N5-methyl-THF) which results in depletion of the active folate pool. The active folate pool is required for purine and thymine nucleotide biosynthesis needed for DNA synthesis. Bone marrow erythroblasts begin to enlarge in preparation for cell division but, due to loss of nucleotide synthesis, they remain as megaloblasts.
In cysteine synthesis, homocysteine condenses with serine to produce cystathionine which is catalyzed by cystathionine β-synthase (cystathionine beta synthase: CBS). The details of CBS are discussed below. Cystathionine is subsequently cleaved by cystathionine γ-lyase (also called cystathionase; also discussed in more detail below) to produce cysteine and α-ketobutyrate. The sum of the latter two reactions is known as trans-sulfuration. Cysteine is used for protein synthesis and other body needs, while the α-ketobutyrate is first converted to propionyl-CoA and then via a 3-step process to the TCA cycle intermediate succinyl-CoA. While cysteine readily oxidizes to form the disulfide cystine, cells contain little if any free cystine because the ubiquitous reducing agent, glutathione, effectively reverses the formation of cystine by a non-enzymatic reduction reaction.
Utilization of methionine in the synthesis of cysteine. The sulfur from the essential amino acid, methionine, is required for the synthesis of cysteine. The synthesis of cysteine represents an extremely important and clinically relevant biochemical pathway. Several vitamins are required for this metabolic pathway to proceed emphasizing the nutritional impact. Folate, pyridoxal phosphate (PLP, B6), and B12 are all necessary for cysteine synthesis. The enzyme methionine synthase requires both folate and B12 for activity. Deficiency in either of these vitamins contributes to homocysteinemia and also to the development of macrocytic (megaloblastic) anemias. Cystathionine β-synthase is a PLP requiring enzyme demonstrating why B6 deficiency is also associated with the development of homocysteinemia.
In addition to methionine synthase, two other key enzymes of the methionine to cysteine biosynthesis pathway are cystathionine β-synthase (cystathionine beta synthase: CBS) and cystathionine γ-lyase (cystathionase). Both of these enzymes require pyridoxal phosphate (PLP: derived from vitamin B6) as a cofactor, and both are under regulatory control. Cystathionine γ-lyase is also negatively regulated by cysteine-mediated allosteric control. In addition, cysteine inhibits the expression of the cystathionine β-synthase gene. Cystathionine β-synthase is encoded by the CBS gene located on chromosome 21q22.3 which is composed of 24 exons which generate at least three alternatively spliced mRNAs. Cystathionine γ-lyase is encoded by the CTH gene located on chromosome 1p31.1 and is composed of 13 exons that undergo alternative splicing generating three isoform encoding mRNAs. Genetic defects are known for both the CBS gene (see next section) and the cystathionine γ-lyase gene. Missing or impaired cystathionine γ-lyase leads to excretion of cystathionine in the urine but does not have any other untoward effects. Rare cases are known in which cystathionine γ-lyase is defective and operates at a low level. This genetic disease leads to methioninuria with no other consequences.back to the top
Homocysteinemias (homocystinemias) represent a family of inherited disorders resulting from defects in several of the genes involved in the conversion of methionine to cysteine. As the name implies, these disorders result in elevated levels of homocysteine and homocystine in the blood, where the elevated urine output of the metabolite is referred to as homocysteinurina or homocystinuria. Homocystine is a disulfide-bonded homodimer of two homocysteines. This is similar to the formation of cystine from two cysteines as diagrammed in the Figure below. In addition to homocysteinuria, patients excrete elevated levels of methionine and metabolites of homocysteine. The most common causes of homocysteinemia are defects in the cystathionine β-synthase (CBS) gene. Homocysteinemia is often associated with mental retardation, although the complete syndrome is multifaceted and many individuals with this disease are mentally normal, while others experience variable levels of developmental delay along with learning problems. Common symptoms of homocysteinemia are dislocated optic lenses (ectopia lentis), osteoporosis, lengthening and thinning of the long bones, and an increased risk of abnormal blood clotting (thromboembolism). The nature of the lens dislocation (subluxation), evident in homocysteinemia patients, can serve as a differential diagnostic tool. Lens dislocation is also found in patients suffering from Marfan syndrome, which is a connective tissue disorder caused by defects in the fibrillin gene (FBN1). In homocysteinemia the lens subluxation occurs in a downward and inward direction, whereas in Marfan syndrome the lens subluxation occurs upward and outward. Some instances of genetic homocysteinemia respond favorably to pyridoxine therapy suggesting, that in these cases the defect in CBS is a decreased affinity for the cofactor, pyridoxal phosphate.
Homocysteinemia can also result from vitamin deficiencies due to the role of the co-factor forms of B6, B12, and folate in the overall metabolism of methionine. Vitamin B6 (as pyridoxal phosphate) is required for the activity of CBS and cystathionine γ-lyase and the homocysteinemia that results with B6 deficiency is also associated with elevated methionine levels in the blood. Vitamin B12 and folate (as N5-methyl-THF) are required for the methionine synthase reaction so a deficiency of either vitamin can result in homocysteinemia presenting with reduced levels of plasma methionine. The enzyme methylmalonyl-CoA mutase also requires B12 and so a homocysteinuria resulting from a deficiency in this vitamin is also associated with methylmalonic academia. Indeed, the measurement of serum methionine and methylmalonic acid in cases of homocysteinemia allows for a differential diagnosis of the nutritional (non-genetic) cause.
Elevated levels of homocysteine in the blood have been shown to correlate with cardiovascular dysfunction. The role of homocysteine in cardiovascular disease is related to its ability to induce a state of inflammation. Homocysteine serves as a negatively charged surface that attracts the contact phase of the intrinsic pathway of blood coagulation. Activation of the intrinsic coagulation cascade leads to inappropriate thrombolytic events as well as resulting in increases in inflammatory cytokine release from leukocytes that are activated as a result of the pro-coagulant state. Therefore, it is important to ensure that proper function of the methionine synthase reaction is maintained. Although it would be assumed that increased intake of vitamin B12 should lead to increased conversion of homocysteine to methionine and thus, reduced levels of circulating homocysteine, controlled studies have shown that this does not occur.back to the top
As the name implies, cystinuria is a disorder associated with excess cystine in the urine. Cystine is the oxidized disulfide homodimer of two cysteines. Cystinuria is an autosomal recessive disorder that results from a failure of the renal proximal tubules to reabsorb cystine that was filtered by the glomerulus. The disorder results from defects in either of the two protein subunits of the cystine transporter which is distinct from the renal cysteine transporter. In addition to excess cystine in the urine, the disorder is also associated with increased urinary excretion of dibasic amino acids arginine, lysine, and ornithine. However, clinical consequences are only associated with the increased urinary cystine and is due to the poor solubility of this homodimeric compound. Cystine will precipitate in the urine resulting in the formation of renal calculi (stones) that can lead to renal failure. The two subunits of the cystine transporter are encoded by the SLC3A1 and SLC7A9 genes that encode the basic amino acid transport protein (rBAT) and the functional subunit that transports neutral and basic amino acids (b(0,+)AT; where the AT stands for amino acid transporter), respectively.
Common treatments for patients with cystinuria are to decrease protein and salt intake as well as to ensure increased hydration as this will dilute the cystine in the urine reducing the potential for crystal formation. In addition, patients are given drugs, such as acetazolamide (a carbonic anhydrase inhibitor principally utilized in the treatment of glaucoma and certain forms of hypertension), which alkalizes the urine thereby reducing the potential for urinary precipitation of cystine. In addition, thiol drugs can be used to compete for the formation of cystine. These drugs include captopril [an angiotensin converting enzyme (ACE) inhibitor used principally in the treatment of hypertension], D-penicillamine (a chelator drug used in the treatment of Wilson disease, lead poisoning, and rheumatoid arthritis), and alpha-mercaptopropionylglycine, α-MPG (a second-generation chelating drug).back to the top
Tyrosine is produced in cells by hydroxylating the essential amino acid phenylalanine. This relationship is much like that between cysteine and methionine. Half of the daily requirement for phenylalanine is for the production of tyrosine; if the diet is rich in tyrosine itself, the requirements for phenylalanine can be reduced by about 50%.
Phenylalanine hydroxylase is a mixed-function oxygenase: one atom of oxygen is incorporated into water and the other into the hydroxyl of tyrosine. The reductant is the tetrahydrofolate-related cofactor tetrahydrobiopterin, which is maintained in the reduced state by the NADH-dependent enzyme, dihydropteridine reductase (DHPR). Phenylalanine hydroxylase is encoded by the PAH gene located on chromosome 12q22–q24.2 and is composed of 13 exons that encode a protein of 452 amino acids. Human dihydropteridine reductase is produced by the quinoid dihydropteridine reductase gene (symbol: QDPR) located on chromosome 4p15.31 and is composed of 7 exons that encode a protein of 244 amino acids.
Missing or deficient phenylalanine hydroxylase results in hyperphenylalaninemia. Hyperphenylalaninemia is defined as a plasma phenylalanine concentration greater than 2mg/dL (120μM). The most widely recognized hyperphenylalaninemia (and most severe) is the genetic disease known as phenlyketonuria (PKU). Patients suffering from PKU have plasma phenylalanine levels >1000μM, whereas the non-PKU hyperphenylalaninemias exhibit levels of plasma phenylalanine <1000μM. Untreated PKU leads to severe mental retardation. The mental retardation is caused by the accumulation of phenylalanine, which becomes a major donor of amino groups in aminotransferase activity and depletes neural tissue of 2-oxoglutarate (α-ketoglutarate). This absence of 2-oxoglutarate in the brain shuts down the TCA cycle and the associated production of aerobic energy, which is essential to normal brain development.
The product of phenylalanine transamination, phenylpyruvic acid, is reduced to phenylacetate and phenyllactate, and all 3 compounds appear in the urine. The presence of phenylacetate in the urine imparts a "mousy" odor. If the problem is diagnosed early, the addition of tyrosine and restriction of phenylalanine from the diet can minimize the extent of mental retardation.
Because of the requirement for tetrahydrobiopterin in the function of phenylalanine hydroxylase, deficiencies in DHPR can manifest with hyperphenylalaninemia. However, since tetrahydrobiopterin is a cofactor in several other enzyme catalyzed reactions (e.g. see the synthesis of the tyrosine- and tryptophan-derived neurotransmitters as well as nitric oxide in Specialized Products of Amino Acids), the effects of missing or defective DHPR cause even more severe neurological difficulties than those usually associated with PKU caused by deficient phenylalanine hydroxylase activity.back to the top
Glutamate is the precursor of both proline and ornithine with Δ1-pyrroline-5-carboxylate serving as a branch point intermediate leading to one or the other of these two products. While ornithine is not one of the 20 amino acids used in protein synthesis, it plays a significant role as the acceptor of carbamoyl phosphate in the urea cycle. Ornithine serves an additional important role as the precursor for the synthesis of the polyamines. The production of ornithine from glutamate is important when dietary arginine, the other principal source of ornithine, is limited. The synthesis of ornithine from glutamate occurs only in the intestines. The conversion of glutamate to Δ1-pyrroline-5-carboxylate is catalyzed by a bi-functional enzyme that is a member of the aldehyde dehydrogenase family. This enzyme, aldehyde dehydrogenase 18 family, member A1 (encoded by the ALDH18A1 gene), possess both γ-glutamyl kinase activity and an NADPH-dependent γ-glutamylphosphate reductase activity. The ALDH18A1 encoded enzyme is also known as delta-1-pyrroline-5-carboxylate synthase (P5CS). The Δ1-pyrroline-5-carboxylate intermediate in this pathway can exist as the open-chain tautomeric compound glutamate γ-semialdehyde which can be transaminated to ornithine via the action of ornithine aminotransferase. Ornithine aminotransferase utilizes glutamate as the amino donor and releases 2-oxoglutarate (α-ketoglutarate). The ALDH18A1 gene is located on chromosome 10q24.3 and is composed of 18 exons that generate two alternatively spliced mRNAs encoding isoform 1 (795 amino acids) and isoform 2 (793 amino acids) versions of the enzyme. Mutations in the ALDH18A1 gene result is a disorder charaterized by hyperammonemia, hypoornithinemia, hypocitrullinemia, hypoargininemia and hypoprolinemia. This disorder is also associated with CNS degeneration, connective tissue disruption, and cataract formation. Ornithine aminotransferase is encoded by the OAT gene located on chromsome 10q26 and is composed of 12 exons that generate two alternatively spliced mRNAs.
The fate of Δ1-pyrroline-5-carboxylate (and its open-chain tautomer, glutamate γ-semialdehyde) depends on prevailing cellular conditions. Ornithine production occurs from the semialdehyde compound via a simple glutamate-dependent transamination, producing ornithine. When arginine concentrations become elevated, the ornithine contributed from the urea cycle plus that from Δ1-pyrroline-5-carboxylate inhibit the aminotransferase reaction, with accumulation of Δ1-pyrroline-5-carboxylate as a result. The accumulating Δ1-pyrroline-5-carboxylate can then be reduced to proline by the NAD(P)H-dependent enzyme pyrroline-5-carboxylate reductase 1 (PYCR1). The PYCR1 gene is located on 17q25.3 and is composed of 9 exons five alternatively spliced mRNAs that encode four different isoforms of the enzyme.
Synthesis of ornithine and proline. Glutamate serves as the precursor for the synthesis of both ornithine and proline which are derived from the Δ1-pyrroline-5-carboxylate intermediate in the pathway. Formation of Δ1-pyrroline-5-carboxylate occurs via the action of the bi-functional enzyme, aldehyde dehydrogenase 18 family, member A1 (also known as delta-1-pyrroline-5-carboxylate synthase). The transamination of the tautomeric form of Δ1-pyrroline-5-carboxylate (glutamate γ-semialdehyde) results in the generation of ornithine. The reduction of Δ1-pyrroline-5-carboxylate to proline occurs via the action of pyrroline-5-carboxylate reductase 1. PRODH is proline dehydrogenase, the first enzyme in the pathway of proline catabolism which converts proline back to Δ1-pyrroline-5-carboxylate.back to the top
The main pathway to de novo biosynthesis of serine starts with the glycolytic intermediate 3-phosphoglycerate. An NADH-linked dehydrogenase (3-phosphoglycerate dehydrogenase) converts 3-phosphoglycerate into a keto acid, 3-phosphohydroxypyruvate, suitable for subsequent transamination. The aminotransferase, phosphoserine aminotransferase 1, utilizing glutamate as a donor, produces 3-phosphoserine, which is converted to serine by phosphoserine phosphatase. The phosphoserine phosphatase gene (symbol: PSPH) is located on chromsome 7p11.2 which is in a region of chromosome 7 that is deleted in Williams-Beuren syndrome, WBS (also called Williams syndrome, WS). WBS is associated with multiple organ system involvement typically showing supravalvular aortic stenosis (SVAS), mental retardation, and distinctive facial features. Phosphoglycerate dehydrogenase is encoded by the PHGDH gene which is located on chromosome 1p12 and is composed of 17 exons that generate a protein of 533 amino acids. Phosphoserine aminotransferase 1 is encode by the PSAT1 gene located on chromosome 9q21.2 and is composed of 9 exons that generate two alternatively spliced mRNAs encoding isoform 1 (370 amino acids; also called PSAT1β beta) and isoform 2 (324 amino acids; also called PSAT1α alpha). The PSPH gene is composed of 12 exons that encode a 225 amino acid protein.
As indicated below, serine can be derived from glycine (and visa versa) by a single step reaction that involves serine hydroxymethyltransferase (SHMT; also called glycine hydroxymethyltransferase) and tetrahydrofolate (THF). Indeed, the interconversion of serine and glycine via the involvement of THF represents the major pathway for the generation of N5,N10-methylene-THF which of a member of the active pool of folate derivatives. N5,N10-methylene-THF is required for purine nucleotide and thymine nucleotide biosynthesis. Humans express two serine hydroxymethyltransferase genes, one is a soluble enzyme the other is located in the mitochondria. The soluble enzyme is derived from the SHMT1 gene ocated on chromosome 17p11.2 which is composed of 13 exons that generate three alternatively spliced mRNAs. The mitochondrial enzyme is derived from the SHMT2 gene located on chromosome 12q12–q14 which is composed of 14 exons that generate five altrernatively spliced mRNAs that encode three distinct isoforms of the enzyme.
Reactions of serine biosynthesis. Serine can be derived from the glycolytic intermediate, 3-phosphoglycerate, in a three-step reaciton pathway. The first reaction is catalyzed by phosphoglycerate dehydrogenase (PHGDH). The second reaction is a simple transamination catalyzed by phosphoserine aminotransferase 1 (PSAT1) which utilizes glutamate as the amino donor and releases 2-oxoglutarate (α-ketoglutarate). The last step in the reaction pathway is catalyzed by phosphoserine phosphatase (PSPH).
The main pathway to glycine is a one-step reversible reaction catalyzed by serine hydroxymethyltransferase (SHMT). This enzyme is a member of the family of one-carbon transferases and is also known as glycine hydroxymethyltransferase. This reaction involves the transfer of the hydroxymethyl group from serine to the cofactor tetrahydrofolate (THF), producing glycine and N5,N10-methylene-THF. As pointed out in the previous section, there are mitochondrial and cytosolic versions of serine hydroxymethyltransferase. The cytosolic enzyme is encoded by the SHMT1 gene on chromosome 17 and the mitochondrial enzyme is encoded by the SHMT2 gene on chromosome 12. The location of the SMHT1 gene, 17p11.2, resides within the 3.7 Mb region of chromosome 17 that is deleted in Smith-Magenis syndrome, SMS, a disorder associated with behavioral problems, psychomotor retardation, growth delay, speech delay, brachycephaly, midface hypoplasia, hoarse voice.
Glycine is involved in many anabolic reactions other than protein synthesis including the synthesis of purine nucleotides, heme, glutathione, creatine and serine. In addition, glycine functions in the central nervous system as an inhibitory neurotransmitter where it participates in regulating signals that process motor and sensory information that permit movement, vision and audition. Glycine is co-released with GABA which is the primary inhibitory neurotransmitter. Glycine action as a neurotransmitter is a function of the amino acid binding to a specific receptor, GlyR. GlyR is a member of the nicitinicoid receptor superfamily that includes the GABAA receptor (GABAAR), the excitatory nicotinic acetylcholine receptors (nAChR) and the serotonin type 3 receptor (5HT3). GlyR is a heteromeric (pentameric) complex consisting of a complex of either three or four α-subunits and one β-subunit. There are four different α-subunit genes (GLRA1, GLRA2, GLRA3, GLRA4) and a single β-subunit gene (GLRB) in the human genome. The GlyR is a ligand-gated ionotropic receptor that is a chloride channel. In addition to glycine, the GlyR can be activated by several other small amino acids such as alanine and taurine. Glycine is also involved in the modulation of excitatory neurotransmission exerted via glutamate binding to N-methyl-D-aspartate (NMDA) type glutamate receptors.back to the top
Glutamate is synthesized by the reductive amination of 2-oxoglutarate (α-ketoglutarate) catalyzed by glutamate dehydrogenase; it is thus a nitrogen-incorporating reaction. In addition, glutamate arises by aminotransferase reactions, with the amino nitrogen being donated by a number of different amino acids. Thus, glutamate is a general collector of amino nitrogen.
Aspartate is formed in a transamination reaction catalyzed by aspartate transaminase, AST. This reaction uses the aspartate α-keto acid analog, oxaloacetate, and glutamate as the amino donor. Aspartate can also be formed by deamination of asparagine catalyzed by asparaginase.
Asparagine synthetase and glutamine synthetase, catalyze the production of asparagine and glutamine from their respective α-amino acids. Glutamine is produced from glutamate by the direct incorporation of ammonia; and this can be considered another nitrogen incorporating reaction. Asparagine, however, is formed by an amidotransferase reaction. The glutamine synthetase enzyme is encoded by the glutamate-ammonia ligase gene (symbol: GLUL) which is located on chromosome 1q31 and is composed of 9 exons that generate several alternatively spliced mRNAs, each of which encode the same 373 amino acid protein. Asparagine synthetase is encoded by the ASNS gene which is located on chromosome 7q21.3 and is composed of 15 exons that generate several alternatively spliced mRNAs.
Aminotransferase reactions are readily reversible. The direction of any individual transamination depends principally on the concentration ratio of reactants and products. By contrast, transamidation reactions, which are dependent on ATP, are considered irreversible. As a consequence, the degradation of asparagine and glutamine take place by a hydrolytic pathway rather than by a reversal of the pathway by which they were formed. As indicated above, asparagine can be degraded to aspartate.back to the top
Glutaminase is an important kidney tubule enzyme involved in converting glutamine (from liver and from other tissue) to glutamate and NH4+, with the NH4+ being excreted in the urine. Glutaminase activity is present in many other tissues as well, although its activity is not nearly as prominent as in the kidney. The glutamate produced from glutamine is converted to 2-oxoglutarate (α-ketoglutarate) via the action of glutamate dehydrogenase, making glutamine a glucogenic amino acid. There are two distinct glutaminase genes in humans identified as GLS and GLS2. The GLS gene is located on chromosome 2q32–q34 and is composed of 24 exons that undergo alternative splicing to yield several mRNAs generating two isoforms of the enzyme. The GLS encoded isoforms of glutaminase are primarily expressed in the kidneys. GLS isoform 1 is a protein of 669 amino acids and GLS isoform 2 is a protein of 598 amnio acids. The GLS2 gene encoded glutaminase was originally thought to be liver specific but is in fact expressed in numerous tissues and is important in the glutamate-glutamine cycle in the brain. The GLS2 encoded glutaminase is dependent on inorganic phosphate (Pi) for activity and is, therefore, also referred to as phosphate-activated glutaminase, PAG. The GLS2 gene is located on chromosome 12q13.3 and is composed of 19 exons that undergo alternative splicing to yield several mRNAs that encode four different isoforms of the enzyme.
Asparaginase (see above) is also widely distributed within the body, where it converts asparagine into ammonia and aspartate. Aspartate can serve as an amino donor in transamination reacions yielding oxaloacetate, which follows the gluconeogenic pathway to glucose.
Glutamate and aspartate are important in collecting and eliminating amino nitrogen via glutamine synthetase and the urea cycle, respectively. The catabolic path of the carbon skeletons involves simple 1-step aminotransferase reactions that directly produce net quantities of a TCA cycle intermediate. The glutamate dehydrogenase reaction operating in the direction of 2-oxoglutarate (α-ketoglutarate) production provides a second avenue leading from glutamate to gluconeogenesis.back to the top
Alanine is also important in intertissue nitrogen transport as part of the glucose-alanine cycle (see above). Alanine's catabolic pathway involves a simple aminotransferase reaction that directly produces pyruvate. Generally, pyruvate produced by this pathway will result in the formation of oxaloacetate, although when the energy charge of a cell is low the pyruvate will be oxidized to CO2 and H2O via the PDH complex (PDHc) and the TCA cycle. This makes alanine a glucogenic amino acid.back to the top
The catabolism of arginine begins within the context of the urea cycle. It is ultimately hydrolyzed to urea and ornithine by arginase.
Ornithine, in excess of urea cycle needs, is transaminated to form glutamate γ-semialdehyde which is in equilibrium with its tautomeric compound, Δ1-pyrroline-5-carboxylate. Catabolism of Δ1-pyrroline-5-carboxylate back to glutamate is catalyzed by aldehyde dehydrogenase 4 family, member A1 (also called delta-1-pyrroline-5-carboxylate dehydrogenase, P5CDH). The dehydrogenase is encoded by the ALDH4A1 gene located on chromosome 1p36 and is composed of 17 exons that generate three alternativley spliced mRNAs, two of which encode the same protein.
Proline catabolism involves a two-step process that is essentially a reversal of its synthesis process outlined above. Proline is first converted back to Δ1-pyrroline-5-carboxylate by the enzyme proline dehydrogenase (gene symbol: PRODH). The PRODH gene is located on chromosome 22q11.21 and is composed of 16 exons that generate two alternatively spliced mRNAs. As for the catabolism of ornithine, the resulting Δ1-pyrroline-5-carboxylate is converted to glutamate via the action of ALDH4A1.
The glutamate that results from ornithine and proline catabolism can then be converted to 2-oxoglutarate (α-ketoglutarate) in a transamination reaction. Therefore, ornithine and proline are both glucogenic. Since arginine is metabolized to urea and ornithine, and the resulting ornithine is a glucogenic precursor, arginine is also a glucogenic amino acid.
Catabolism of arginine, ornithine, and proline. The catabolism of ornithine and proline is essentially a reversal of their synthesis from glutamate. Proline is oxidized back to Δ1-pyrroline-5-carboxylate via the action of proline dehydrogenase (PRODH). Ornithine can be deaminated to Δ1-pyrroline-5-carboxylate via a reversal of the ornithine aminotransferase (OAT) reaction. The resulting Δ1-pyrroline-5-carboxylate is oxidized to glutamate via the action of aldehyde dehydrogenase 4 family, member A1, ALDH4A1 (also called delta-1-pyrroline-5-carboxylate dehydrogenase, P5CDH). Arginine catabolism/metabolism involves several pathways, with the major catabolic pathway being its role in the urea cycle. In some tissues arginine serves as the precursor for nitric oxide (NO) production via the action of nitric oxide synthases (NOS). The citrulline byproduct of the NOS reaction can feed back into arginine synthesis via the hepatic urea cycle enzymes argininosuccinate synthetase (ASS1) and argininosuccinate lyase (ASL). Arginine also serves as the precursor for creatine synthesis and, therefore, arginine can be excreted in the urine as creatine byproduct, creatinine. The cycling of citrulline back to arginine involves the urea cycle enzymes, argininosuccinate synthetase (ASS1) and argininosuccinate lyase (ASL).
The conversion of serine to glycine and then glycine oxidation to CO2 and NH3, with the production of two equivalents of N5,N10-methyleneTHF, was described above in the section on glycine biosynthesis. Serine can be catabolized back to the glycolytic intermediate, 3-phosphoglycerate, by a pathway that is essentially a reversal of serine biosynthesis. However, the enzymes are different. Although it has been demonstrated in mammals such as rodents and dogs that serine can be converted to pyruvate through a deamination reaction catalyzed by serine/threonine dehydratase, this activity of the enzyme appears to be lacking in humans.back to the top
There are at least 3 pathways for threonine catabolism that have been identified in yeasts, insects, and vertebrates including mammals. The principal threonine catabololizing pathway in humans involves glycine-independent serine/threonine dehydratase yielding α-ketobutyrate which is further catabolized to propionyl-CoA. Serine/threonine dehydratase is expressed at high levels only in the liver. It appears that in newborn infants catabolism of threonine occurs exclusively via the action of the serine/threonine dehydratase. Therefore, it is presumed that this is the predominant threonine catabolizing pathway in humans. The resulting propionyl-CoA is converted, via a mitochondrially-localized three reaction ATP-dependent pathway, to succinyl-CoA. The succinyl-CoA can then enter the TCA cycle for further oxidation. The enzymes required for this conversion are propionyl-CoA carboxylase, methylmalonyl-CoA epimerase, and methylmalonyl-CoA mutase, respectively. Propionyl-CoA carboxylase is called an ABC enzyme due to the requirements for ATP, Biotin, and CO2 for the reaction. This propionyl-CoA conversion pathway is also required for the metabolism of the amino acids valine, isoleucine, and methionine (see below), and odd-chain fatty acids. For this reason this three-step reaction pathway is often remembered by the mnemonic as the VOMIT pathway, where V stands for valine, O for odd-chain fatty acids, M for methionine, I for isoleucine, and T for threonine.
Propionyl-CoA carboxylase functions as a heterodimeric enzyme and the two different subunits (alpha and beta) are encoded by two different genes, PCCA and PCCB. The PCCA gene is located on chromosome 13q32 and is composed of 27 exons that generate three alternatively spliced mRNAs. The PCCB gene is located on 3q21–q22 and is composed of 17 exons that generate two alternatively spliced mRNAs. Methylmalony-CoA epimerase is encoded by the MCEE gene located on chromosome 2p13.3 and is composed of 4 exons that encode a 176 amino acid protein. Methylmalonyl-CoA mutase is encoded by the MUT gene located on chromosome 6p12.3 and ius composed of 13 exons that encode a protein of 750 amino acids.
The second pathway of threonine catabolism utilizes serine hydroxymethyltransferase. As indicated above in the Glycine biosynthesis section, this enzyme belongs to a family of one-carbon transferases and is alternatively named glycine hydroxymethyltransferase or threonine aldolase. The products of this reaction are acetyl-CoA and glycine. The glycine can be converted to serine via the same enzyme and the serine is then catabolized as described above yielding pyruvate and NH4+. Thus, via this catabolic pathway threonine yields ketogenic and glucogenic byproducts. In humans it appears that threonine aldolase is actually encoded by a non-functional pseudogene, whereas in other mammals and vertebrates (e.g. mice, zebrafish, and clawed frogs) the threonine aldolase gene encodes a functional threonine catabolizing enzyme.
An additional pathway occurs in the mitochondria and is initiated by threonine dehydrogenase yielding α-amino-β-ketobutyrate (2-amino-3-ketobutyrate). The 2-amino-3-ketobutyrate is either converted to acetyl-CoA and glycine, via the action of 2-amino-3-ketobutyrate coenzyme A ligase (also called glycine C-acetyltransfease), or it can spontaneously degrade to aminoacetone which is converted to pyruvate. The threonine dehydrogenase gene in humans appears to be non-functional due to the incorporation of three inactivating mutations. Thus, whereas, this enzyme is a major threonine catabolizing enzyme in other mammals such as mice, it is the serine/threonine dehydratase gene that is most important in threonine catabolism in humans.back to the top
Glycine is classified as a glucogenic amino acid, since it can be converted to serine by serine hydroxymethyltransferase, and serine can be converted back to the glycolytic intermediate, 3-phosphoglycerate or to pyruvate by serine/threonine dehydratase, although the latter reaction (serine to pyruvate) appears not be occur in human tissues. Nevertheless, the main glycine catabolic pathway leads to the production of CO2, ammonia, and one equivalent of N5,N10-methyleneTHF by the mitochondrial enzyme, glycine dehydrogenase (decarboxylating) which is also called the glycine cleavage complex, GCC. The GCC is composed of four mitochondrial proteins encoded by four genes. The protein components of the GCC are the actual glycine dehydrogenase subunit (identified as the P subunit: pyridoxal phosphate-dependent), a lipoic acid-containing subunit (the H subunit), a tetrahydrofolate-requiring enzyme called aminomethyltransferase (the T subunit), and dihydrolipoamide dehydrogenase (the L subunit). The P subunit is encoded by the GLCD gene located on chromosome 9p22 and is composed of 25 exons that encode a protein of 1020 amino acids. The H subunit is encoded by the GCSH gene located on chromosome 16q23.2 and is composed of 5 exons that generate two splice variant mRNAs, only one of which encodes a functional protein of 173 amino acids. The T subunit (aminomethyltransferase) is encoded by the AMT gene located on chromosome 3p21.31 and is composed of 9 exons that generate four alternatively spliced mRNAs generating four isoforms of the enzyme. The L subunit is encoded by the DLD gene located on chromosome 7q31–q32 and is composed of 14 exons that generate multiple alternatively spliced mRNAs. The DLD encoded protein is also found as a subunit of several other important dehydrogenase complexes: the pyruvate dehydrogenase complex (PDHc), the 2-oxoglutarate (α-ketoglutarate) dehydrogenase complex, and the branched-chain keto-acid dehydrogenase (BCKD) complex. Deficiencies in the H, P, or T proteins results in glycine encephalopathy which is characterized by nonketotic hyperglycinemia. These gene defects result in severe mental retardation that is due to highly elevated levels of glycine in the CNS.
There are several pathways for non-protein disposition of cysteine that include both metabolism and catabolism. The major cysteine catabolic pathway in humans occurs via the action of cysteine dioxygenase type 1 (gene symbol: CDO1). CDO1 oxidizes the sulfhydryl group of cysteine to sulfinate, producing the intermediate cysteine sulfinate. The CDO1 gene is located on chromosome 5q23.2 and is composed of 6 exons that encode a 200 amino acid protein.
Catabolism of cysteine sulfinate proceeds through transamination (catalyzed by cytosolic AST) to β-sulfinylpyruvate (3-sulfinylpyruvate) which then undergoes desulfuration yielding pyruvate and bisulfite, (HSO3–) which is in equilibrium with sulfite (SO32–) at pH 7.2. The enzyme sulfite oxidase (gene symbol: SUOX) then catalyzes the conversion of sulfite to sulfate. The SUOX encoded enzyme is somewhat unique in that it uses the oxygen atom from H2O to convert sulfite to sulfate, (SO42–) and releases two protons (H+). The SUOX gene is located on chromosome 12q13.2 and is composed of 7 exons that encode a protein of 545 amino acids. The enzyme cysteine desulfurase (encoded by the NFS1 gene) is another important enzyme associated with cysteine catabolism. Cysteine desulfurase removes the sulfur from cyteine yielding alanine. The sulfur remains associated with cysteine desulfurase and is subsequently transferred to numerous enzymes that possess iron-sulfur clusters for their activity.
Other than protein, the most important metabolic products derived from cysteine are glutathione (GSH), the bile salt modifying compound, taurine, and as a source of the sulfur for coenzyme-A synthesis. Taurine is used to form the bile acid conjugates taurocholate and taurochenodeoxycholate. Taurine synthesis occurs primarily in the liver since this is the only bile acid synthesizing tissue in the body However, taurine can be transported to the blood and disseminated to other tissues. Taurine is derived from the cysteine catabolism intermediate, cysteine sulfinate. Cysteine sulfinate is converted to hypotaurine by the rate-limiting enzyme in taurine synthesis, cysteine sulfinic acid decarboxylase, CSAD (also called sulfinoalanine decarboxylase). Oxidation of hypotaurine to taurine is thought to occur spontaneously, i.e non-enzymatically.
Pathways of cysteine catabolism. Catabolism of cysteine is responsible for the release and or transfer of the sulfur from this amino acid. The catabolism of cysteine can also involve a metabolic pathway as is the case for taurine synthesis. Cysteine catabolism and taurine synthesis both begin with the oxidation to cysteine sulfinic acid catalyzed by cysteine dioxygenase. Cysteine sulfinate is converted to taurine via the action of cysteinesulfinate decarboxylase. Catabolism of cysteine sulfinate to sulfate ion first involves a transamination that releases 3-sulfinpyruvate that spntaneously decomposes to bisulfite ion and pyruvate. The transaminase responsible for this reaction is the soluble form of aspartate transaminase which is encoded by the GOT1 gene. The bisulfite ion is in ionic equilibrium with sulfite ion which is then converted to the sulfate ion via the action of sulfite oxidase. The released sulfate can be used for PAPS synthesis as described in the following Figure.
The enzyme cystathionase (cystathionine γ-lyase) can also transfer the sulfur from one cysteine to another generating thiocysteine and pyruvate. Transamination of cysteine yields β-mercaptopyruvate which then reacts with sulfite, (SO32–), to produce thiosulfate, (S2O32–) and pyruvate. Both thiocysteine and thiosulfate can be used by sulfurtransferases to incorporate sulfur into cyanide ion, (CN–), thereby detoxifying the cyanide to thiocyanate. These sulfurtransferase enzymes contain domains called rhodanese domains since they were first identifed in a mitochondrial enzyme that was originally called rhodanese (thiosulfate sulfurtransferase, TST). Another rhodanese domain-containing enzyme that is located in the cytosol is called mercaptopyruvate sulfurtransferase (MPST). MPST transfers the sulfur group from 3-mercaptopyruvate to CN– and other thiol compounds.
One of the important uses of the sulfate that is derived from the catabolism of cysteine is as a precursor for the formation of 3'-phosphoadenosine-5'-phosphosulfate, (PAPS). PAPS is used for the transfer of sulfate to biological molecules such as the sugars of the glycosphingolipids.
Two-step reaction for synthesis of PAPS. The synthesis of PAPS involves the addition of sulfate at the β (beta) position of the phosphates of ATP with the resultant loss of the γ (gamma) phosphate generating adenosine 5'-phosphosulfate, APS. APS is then phosphorylated at the 3'-position of the ribose moiety forming the ultimate product, PAPS. Synthesis of PAPS in humans is catalyzed by the bi-functional enzyme 3'-phosphoadenosine 5'-phosphosulfate synthase, PAPSS. PAPSS possesses both the ATP sulfurylase and APS kinase activities that are associated with two separate enzymes in yeasts, bacteria, and plants. Humans express two PAPSS genes identified as PAPSS1 and PAPSS2.back to the top
The principal fates of the essential amino acid methionine are incorporation into polypeptide chains, and use in the production of cysteine and α-ketobutyrate via the reaction pathway involving the synthesis of SAM and cysteine as described above. The transulfuration reactions that produce cysteine from homocysteine and serine also produce α-ketobutyrate, the latter being converted first to propionyl-CoA and then via a 3-step process to succinyl-CoA.
In the catbolism of methionine the α-ketobutyrate is converted to propionyl-CoA. The propionyl-CoA is converted, via a mitochondrially-localized three reaction ATP-dependent pathway, to succinyl-CoA. The succinyl-CoA can then enter the TCA cycle for further oxidation. The enzymes required for this conversion are propionyl-CoA carboxylase, methylmalonyl-CoA epimerase, and methylmalonyl-CoA mutase, respectively. Propionyl-CoA carboxylase is called an ABC enzyme due to the requirements for ATP, Biotin, and CO2 for the reaction. The clinical significance of methylmalonyl-CoA mutase in this pathway is that it is one of only two enzymes that requires a vitamin B12-derived co-factor for activity. The other B12-requiring enzyme is methionine synthase (see the Cysteine Synthesis section above). This propionyl-CoA conversion pathway is also required for the metabolism of the amino acids valine, isoleucine, and threonine and odd-chain fatty acids. For this reason this three-step reaction pathway is often remembered by the mnemonic as the VOMIT pathway, where V stands for valine, O for odd-chain fatty acids, M for methionine, I for isoleucine, and T for threonine.
Propionyl-CoA carboxylase functions as a heterodimeric enzyme and the two different subunits (alpha and beta) are encoded by two different genes, PCCA and PCCB. The PCCA gene is located on chromosome 13q32 and is composed of 27 exons that generate three alternatively spliced mRNAs. The PCCB gene is located on chromosome 3q21–q22 and is composed of 17 exons that generate two alternatively spliced mRNAs. Methylmalonyl-CoA epimerase is encoded by the MCEE gene located on chromosome 2p13.3 and is composed of 4 exons that encode a 176 amino acid protein. Methylmalonyl-CoA mutase is encoded by the MUT gene located on chromosome 6p12.3 and is composed of 13 exons that encode a protein of 750 amino acids.
Regulation of the methionine metabolic pathway is based on the availability of methionine and cysteine. If both amino acids are present in adequate quantities, SAM accumulates and is a positive effector on cystathionine β-synthase, encouraging the production of cysteine and α-ketobutyrate (both of which are glucogenic). However, if methionine is scarce, SAM will form only in small quantities, thus limiting cystathionine β-synthase activity. Under these conditions accumulated homocysteine is remethylated to methionine, using N5-methyl-THF as the methyl donor.back to the top
This group of essential amino acids is identified as the branched-chain amino acids, BCAAs. Because this arrangement of carbon atoms cannot be made by humans, these amino acids are an essential element in the diet. The catabolism of all three amino acids occurs in most cells but at highest rates in skeletal muscle. BCAA catabolism yields both NADH and FADH2 which can be utilized for ATP generation which is a primary reason for their high rates of catabolism in skeletal muscle. The catabolism of all three of these amino acids uses the same enzymes in the first two steps. The first step in each case is a transamination using a pyridoxal phosphate-dependent BCAA aminotransferase (termed a branched-chain aminotransferase, BCAT), with 2-oxoglutarate (α-ketoglutarate) as amine acceptor.
Humans express two genes that encode BCAT activity. These two genes are identified as BCAT1 and BCAT2. The primary protein encoded by the BCAT1 gene is a cytosolic version of the enzyme and the protein is identified as BCATc. The primary protein encoded by the BCAT2 gene is a mitochondrial version of the enzyme and this protein is designated BCATm. The BCAT1 gene is located on chromosome 12p12.1 and is composed of 13 exons that generate five alternatively spliced mRNAs, each of which encode a distinct isoform. BCAT1 isoform 1 is a 386 amino acid protein. BCAT1 isoform 2 is a 349 amino acid protein. BCAT1 isoform 3 is a 325 amino acid protein. BCAT1 isoform 4 is a 398 amino acid protein. BCAT1 isoform 5 is a 385 amino acid protein. The BCAT2 gene is located on chromosome 19q13 and is composed of 12 exons that generate three alternatively spliced mRNAs that encode three different isoforms. BCAT2 isoform a is a 392 amino acid protein which is also referred to as PP18a. BCAT2 isoform b is a 300 amino acid protein which is also referred to as PP18b. The isoform b protein is found in the cytosol. BCAT2 isoform c is a 352 amino acid protein. Expression of the BCAT1 gene is restricted to only a few tissues types. The BCAT1 gene represents the primary BCAT expressing gene in the brain. Expression of BCAT2 is widely distributed among numerous tissues. Although detectable in the fetal liver, the adult liver does not express either BCAT gene.
The metabolism of the branched-chain amino acids is critical to overall nitrogen homeostasis in the brain and to the maintenance of proper levels of the excitatory neurotransmitter, glutamate. The critical enzymes that are necessary for this homeostatic process are the BCATc and BCATm isoforms of the BCAA aminotransferases. Within the brain different populations of cells express predominantly BCATc while others express predominantly BCATm and this differential distribution is what is important in overall neuronal nitrogen homeostasis.
As a result of the BCAT reaction, three different α-keto acids are produced and are oxidized using a common branched-chain α-keto acid dehydrogenase (BCKD) complex, yielding the three different CoA derivatives. Subsequently the metabolic pathways diverge, producing many intermediates. The BCKD complex is one of three dehydrogenase complexes whose vitamin-derived cofactor requirements can be remembered by the mnemonic: Tender Loving Care For Nancy, where the T stands for thiamine, the L for lipoic acid, the C for coenzyme A (CoA), the F for riboflavin, and the N for niacin. The other two dehydrogenase complexes are the PDHc and the 2-oxoglutarate dehydrogenase complexes associated with the TCA cycle.
The BCKD complex is a multimeric enzyme composed of three catalytic subunits. The E1 portion of the complex is a thiamine pyrophosphate (TPP)-dependent decarboxylase with a subunit structure of α2β2. The E2 portion is a dihydrolipoamide branched-chain transacylase composed of 24 lipoic acid-containing polypeptides. The E3 portion is a homodimeric flavoprotein identified as dihydrolipoamide dehydrogenase, DLD. The activity of BCKD is regulated by two additional subunits, a kinase and a phosphatase that reversibly phosphorylate/dephosphorylate, respectively, the complex. The phosphorylated enzyme is inactive. The E1α gene (symbol: BCKDHA) is located on chromosome 19q13.1–q13.2, spans 55 kb and contains 9 exons that generate two alternatively spliced mRNAs that encode alpha subunit isoform 1 (445 amino acids) and alpha subunit isoform 2 (444 amino acids). The E1β gene (symbol: BCKDHB) is located on chromosome 6q14.1 and is composed of 16 exons that genereate two alternatively spliced mRNAs that encode the same 392 amino acid protein. The E2 gene (symbol: DBT) is located on chromosome 1p31, spans 68 kb and contains 13 exons that encode a protein of 482 amino acids. The E3 gene (symbol: DLD) is located on chromosome 7q31–q32, spans 20 kb and contains 14 exons that generate several alternatively spliced mRNAs. The DLD gene encodes the same dihydrolipoamide dehydrogenase subunits found in the PDHc and the 2-oxoglutarate dehydrogenase complexes.
Catabolism of the branched-chain amino acids. The three branched-chain amino acids, isoleucine, leucine, and valine enter the catabolic pathway via the action of the same two enzymes. The initial deamination of all three amino acids is catalyzed by one of two branched-chain amino acid transaminases (BCATc or BCATm). The resulting α-ketoacids are then oxidatively decarboxylated via the action of the enzyme complex, branched-chain ketoacid dehydrogenase (BCKD). The BCKD reaction generates the CoA derivatives of the decarboxylated ketoacids while also generating the reduced electron carrier, NADH. After these first two reactions the remainder of the catabolic pathways for the three amino acids diverges. The third reaction of branched-chain amino acid catabolism involves a dehydrogenation step that involve three distinct enzymes, one for each of the CoA derivatives generated via the BCKD reaction. This latter dehydrogenation step also yields additional reduced electron carrier as FADH2. The third reaction of isoleucine catabolism involves the enzyme short/branched-chain acyl-CoA dehydrogenase (SBCAD). The SBCAD enzyme is encoded by the ACADSB gene. The third reaction of leucine catabolism involves the enzyme isovaleryl-CoA dehydrogenase (IVD). The third reaction of valine catabolism involves the enzyme isobutyryl-CoA dehydrogenase (IBD). The IBD enzyme is encoded by the acyl-CoA dehydrogenase family, member 8 (ACAD8) gene.
The principal catabolic by-product from valine is propionylCoA, the glucogenic precursor of succinyl-CoA. Isoleucine catabolism terminates with production of acetylCoA and propionylCoA; thus isoleucine is both glucogenic and ketogenic. Leucine gives rise to acetylCoA and acetoacetylCoA, and is thus classified as strictly ketogenic. As pointed out above for the catabolism of methionine, the resulting propionyl-CoA is converted, via a mitochondrially-localized, three reaction, ATP-dependent pathway, to succinyl-CoA. The succinyl-CoA can then enter the TCA cycle for further oxidation. The enzymes required for this conversion are the ABC enzyme propionyl-CoA carboxylase, methylmalonyl-CoA epimerase, and the B12-dependent enzyme methylmalonyl-CoA mutase. This propionyl-CoA conversion pathway is often remembered by the mnemonic as the VOMIT pathway, where V stands for valine, O for odd-chain fatty acids, M for methionine, I for isoleucine, and T for threonine.
Propionyl-CoA carboxylase functions as a heterodimeric enzyme and the two different subunits (alpha and beta) are encoded by two different genes, PCCA and PCCB. The PCCA gene is located on chromosome 13q32 and is composed of 27 exons that generate three alternatively spliced mRNAs. The PCCB gene is located on 3q21–q22 and is composed of 17 exons that generate two alternatively spliced mRNAs. Methylmalony-CoA epimerase is encoded by the MCEE gene located on chromosome 2p13.3 and is composed of 4 exons that encode a 176 amino acid protein. Methylmalonyl-CoA mutase is encoded by the MUT gene located on chromosome 6p12.3 and ius composed of 13 exons that encode a protein of 750 amino acids.
There are a number of genetic diseases associated with faulty catabolism of the BCAAs. The most common defect is in the branched-chain α-keto acid dehydrogenase (BCKD) complex. Since there is only one dehydrogenase enzyme for all three amino acids, all three α-keto acids accumulate and are excreted in the urine. The disease is known as Maple syrup urine disease because of the characteristic odor of the urine in afflicted individuals. Mental retardation in these cases is extensive. Unfortunately, since these are essential amino acids, they cannot be heavily restricted in the diet. The main neurological problems are due to poor formation of myelin in the CNS. Although the outcomes for afflicted individuals used to quite severe with abnormal development and a short life-span, many advances in the treatment of MSUD in recent years have improved the clinical picture. Liver transplantation can result in a relatively normal life for MSUD patients.back to the top
Numerous studies have shown that diets high in protein increase fatty acid oxidation and overall energy expenditure and thus, promote weight loss. In addition, high protein diets are known to improve glucose homeostasis and therefore, can have a positive impact on insulin sensitivity and diabetes. In animal models of obesity and diabetes, increasing the protein to carbohydrate ratio in a high-fat diet results in a delay in the development of obesity while simultaneously improving glucose tolerance. In studies on obese humans, subjects that consumed a milk whey-protein-enriched diet exhibited demonstrable improvement in fatty liver symptoms (hepatic steatosis) and reduced plasma lipid profiles. The composition of whey protein is approximately 65% β-lactoglobulin, 25% α-lactalbumin, and 8% serum albumin. In studies examining the effects of dietary protein on energy expenditure, appetite suppression, and weight loss, whey protein is the more beneficial source when comparing the effects of consumption of whey proteins, soy proteins, or casein.
Whey proteins are enriched in the branched-chain amino acids (BCAA) leucine, isoleucine, and valine and are thus, excellent sources of energy production in skeletal muscle as well as serving as building blocks for muscle protein synthesis. Leucine has been proposed to be the primary mediator of the metabolic changes that occur when consuming a high protein diet. At the molecular level, leucine has been shown to activate the metabolic regulatory kinase known as mammalian target of rapamycin, mTOR. For more information on the activities and regulation of mTOR go to the Insulin Functions page or to the Protein Synthesis page. Activation of skeletal muscle mTOR results in increased protein synthesis and thus, increased energy expenditure. Hypothalamic mTOR activation is also involved in the regulation of feeding behaviors. Of note is the fact that direct injection of leucine into the hypothalamus results in increased mTOR signaling leading to decreased feeding behavior and body weight. This effect is unique to leucine, as direct injection of valine, another BCAA, does not result in hypothalamic mTOR activation nor reductions in food intake or body weight.
The effects of leucine supplementation, on the above described parameters, are not as pronounced as the effects observed when consuming a high-protein diet. This suggests that additional factors are likely involved in the effects of high-protein diets. One of these factors may be that consuming a high protein diet is associated with a reduction in total carbohydrate intake. The reduced carbohydrate intake would thus, be associated with a reduction in hepatic lipogenesis and an increase in adipose tissue lipolysis. Although leucine alone is not as effective as high-protein diets at reducing body weight and food intake it cannot be discounted as an important dietary supplement.
However, it must be pointed out that some controversy surrounds the role of high protein consumption, and in particular leucine intake, in overall metabolic homeostasis. This is due to the fact that some studies in laboratory animals have shown that leucine supplementation results in insulin resistance. This latter effect would certainly lead to an increased likelihood for development of type 2 diabetes. In the typical Western diet consisting of high dairy and meat, the role of leucine in the pathogeneis of type 2 diabetes is suggested by the consequent over activation of mTOR. With respect to diabetes, activation of mTOR results in phosphorylation and activation of the kinase, p70S6K, which in turn phosphorylates the insulin receptor substrate 1 (IRS-1). Phosphorylation of IRS-1 by p70S6K results in reduced insulin-mediated signaling via the insulin receptor, thereby, increasing the metabolic burden on pancreatic β-cells. In addition, increased mTOR activation leads to adipogenesis which can lead to obesity-mediated insulin resistance. Most of the work in laboratory animals demonstrates that the positive effects of increased leucine intake or high-protein diets are most pronounced when the animals are also consuming a high-fat diet. Therefore, it is suggestive that there are definite benefits for overweight and obese individuals to increase their intake of leucine and/or total protein as a means for appetite and weight control. However, although high-protein diets or leucine supplementation are important considerations in a healthy diet, the total amount consumed must be taken into account so as not to lead to excess mTOR activation.back to the top
Phenylalanine normally has only two fates: incorporation into polypeptide chains, and hydroxylation to tyrosine via the tetrahydrobiopterin-requiring phenylalanine hydroxylase (PAH) reaction. Thus, phenylalanine catabolism always follows the pathway of tyrosine catabolism. Tyrosine is equally important for protein biosynthesis as well as an intermediate in the biosynthesis of the catecholamines: dopamine, norepinephrine and epinephrine (see Specialized Products of Amino Acids).
The pathway of tyrosine degradation involves conversion to fumarate and acetoacetate, allowing phenylalanine and tyrosine to be classified as both glucogenic and ketogenic. The catabolism of tyrosine involves five reactions, four of which have been shown to associated with inborn errors in metabolism and three of these result in clinically significant disorders. The first reaction of tyrosine catabolism involves the nuclear genome encoded mitochondrial enzyme tyrosine aminotransferase and generates the corresponding ketoacid, p-hydroxyphenylpyruvic acid. Like most aminotransferase reaction, tyrosine aminotransferase utilizes 2-oxoglutarate (α-ketoglutarate) as the amino acceptor with the consequent generation of glutamate. Tyrosine aminotransferase is encoded by the TAT gene on chromosome 16q22.1 which is composed of 12 exons that generate a protein of 454 amino acids. The second reaction of tyrosine catabolism is catalyzed by p-hydroxyphenylpyruvate dioxygenase which is encoded by the HPD gene located on chromosome 12q24.31 which is composed of 17 exons that generate two alternatively spliced mRNAs. The product of the HPD reaction is homogentisic acid. Homogentisate is oxidized by the second dioxygenase enzyme of tyrosine catabolism, homogentisate oxidase. Homogentisate oxidase is encoded by the homogentisate 1,2-dioxygenase gene (symbol: HDG) located on chromosome 3q13.33 and composed of 16 exons that encode a protein of 445 amino acids. Oxidation of homogentisate yields 4-maleylacetoacetate which is isomerized to 4-fumarylacetoacetate by the enzyme glutathione S-transferase zeta (ζ) 1 which is encoded by the GSTZ1 gene. Glutathione S-transferase zeta 1 was formerly called 4-maleylacetoacetate isomerase or maleylacetoacetate cis-trans-isomerase. The GSTZ1 gene is located on chromosome 14q24.3 and is composed of 12 exons that generate three alternatively spliced mRNAs. Fumarylacetoacetate is hydrolyzed to fumarate and acetoacetate by the enzyme fumarylacetoacetate hydrolase which is encoded by the FAH gene located on chromosome 15q25.1 and is composed of 14 exons that generate a 419 amino acid protein. The fumarate end product of tyrosine catabolism feeds directly into the TCA cycle for further oxidation. The acetoacetate is activated to acetoacetyl-CoA via the action of the mitochondrial ketone body utilization enzyme, succinyl-CoA:3-oxoacid-CoA transferase (SCOT) which is encoded by the OXCT1 (3-oxoacid-CoA transferase 1) gene. Acetoacetate can also be activated in the cytosol by the cytosolic enzyme, acetoacetyl-CoA synthetase (AACS).
Pathway of phenylalanine and tyrosine catabolism. Phenylalanine becomes tyrosine via the action of phenylalanine hydroxylase as discussed in the Tyrosine Biosynthesis section. Therefore, the phenylalanine and tyrosine catabolic pathways are the same. Tyrosine is ultimately degraded to fumarate and acetoacetate througgh a series of five reactions. HPD: hydroxyphenylpyruvate dioxygenase. GSTZ1: glutathione S-transferase zeta 1 which was formerly called 4-maleylacetoacetate isomerase. FAH: fumarylacetoacetate hydrolase.
Inherited mutations in the TAT gene lead to hypertyrosinemia type II (TYRSN2; also called Richner-Hanhart syndrome) which, as the name implies, is associated with elevated tyrosine levels in the blood and, consequently the urine. This form of tyrosinemia is associated with mental retardation, painful corneal eruptions, photophobia, keratitis, and painful palmoplantar hyperkeratosis. Mutations in the HPD gene result in hypertyrosinemia type IIII (TYRSN3). TYRSN3 is an autosomal recessive disease that, in addition to hypertyrosinemia, is associated with mild mental retardation and/or convulsions but these patients do not display hepatic damage as is characteristic of type I hypertyrosinemia. Mutations in the FAH gene result in hypertyrosinemia type I (TYRSN1). TYRSN1 is an autosomal recessive disorder characterized by hypertyrosinemia and progressive liver disease. This disorder also leads to a secondary renal tubular dysfunction resulting in hypophosphatemic rickets. The first inborn error in metabolism ever recognized, alkaptonuria, was demonstrated to be the result of a defect in phenylalanine and tyrosine catabolism. Alkaptonuria is caused by defective homogentisic acid oxidase which is the third enzyme in the tyrosine catabolic pathway. Homogentisic acid accumulation is relatively innocuous, causing urine to darken on exposure to air, but no life-threatening effects accompany the disease. The only untoward consequence of alkaptonuria is ochronosis (bluish-black discoloration of the tissues) and arthritis.back to the top
Like all amino acids, catabolism of lysine can initiate from uptake of dietary lysine or from the breakdown of intracellular protein. Intestinal uptake of lysine involves specific transporter proteins. In most tissues, cationic amino acids are transported principally by a Na+-independent system, specific for L-isomers of lysine, arginine, and ornithine. This transport system is known as the Y(+) system and these transporters are members of the SCL7 family of membrane transporters. There are actually at least three transport mechanisms for lysine transport. One is the aforementioned Y(+) system that can be inhibited by leucine with high affinity when Na+ is present, but this affinity is reduced in the absence of sodium. Another mechanism involves a Na+-independent system that is inhibited by leucine with high affinity only when Na+ is present. An additional transporter is a Na+-dependent transport system that can be inhibited by leucine with high affinity and also by alanine. Once taken up by the intestines, dietary lysine can be incorporated into protein or catabolized.
There are several, at least three, pathways for lysine catabolism but the primary pathway utilized within the liver is one that begins with the formation of an adduct between lysine and 2-oxoglutarate (α-ketoglutarate) called saccharopine. Lysine catabolism is unusual in the way that the ε-amino group is transferred to 2-oxoglutarate and into the general nitrogen pool. The reaction is a transamination in which the ε-amino group is transferred to the α-keto carbon of 2-oxoglutarate forming the metabolite, saccharopine. Unlike the majority of transamination reactions, this one does not employ pyridoxal phosphate as a cofactor. The formation of saccharopine and its hydrolysis to α-aminoadipic-6-semialdehyde is catalyzed by the bifunctional enzyme α-aminoadipic semialdehyde synthase. This reaction results in the amino nitrogen remaining with the α-carbon of 2-oxoglutarate, producing glutamate and α-aminoadipic-6-semialdehyde. Because this transamination reaction is not reversible, lysine is an essential amino acid. Mammalian α-aminoadipic semialdehyde synthase is encoded by the AASS gene found on chromosome 7q31.3 and is composed of 26 exons encoding a protein of 926 amino acids. The N-terminal half of the AASS protein harbors the lysine:2-oxoglutarate reductase activity and the C-terminal half harbors the saccharopine dehydrogenase activity. The ultimate end-product of lysine catabolism, via this saccharopine pathway, is acetoacetyl-CoA.
Genetic deficiencies in either of the first two reactions of the saccharopine pathway of lysine catabolism result in familial hyperlysinemia associated with psychomotor retardation. Since these two reactions are catalyzed by the bifunctional enzyme, AASS, defects can be found in either the N-terminal lysine:2-oxoglutarate reductase activity or the C-terminal saccharopine dehydrogenase activity. These deficiencies are observed in individuals who excrete large quantities of urinary lysine and some saccharopine.
One of the other minor pathways of lysine catabolism is the pipecolic acid pathway. L-pipecolic acid (2-carboxypiperdine) was known to be a widely distributed non-protein amino acid in plants and to be derived from lysine catabolism in mammals. Originally it was thought that the degradation of lysine to pipecolate was the major catabolic pathway for this amino acid. Although it is now known that this product of lysine catabolism reflects a minor catabolic pathway, there is clinical significance to this pathway. In addition, lysine catabolism via the pipecolic acid pathway may play a significant role in the central nervous system. Lysine catabolism via this pathway involves conversion to α-keto-ε-amino-caproic acid and then to pipecolic acid. Pipecolic acid then is ultimately converted to α-aminoadipic semialdehyde which is also a product of the saccharopine pathway of lysine catabolism. Formation of α-aminoadipic semialdehyde from pipecolic acid is catalyzed by α-aminoadipic semialdehyde dehydrogenase (AASA dehydrogenase). AASA dehydrogenase is also known as antiquitin (ATQ1) and is encoded by the aldehyde dehydrogenase 7 family member A1 gene (ALDH7A1). The ALDH7A1 gene is located on chromosome 5q31 composed of 19 exons that generate three alternatively spliced mRNAs generating three isoforms of the enzyme. Mutations in the ALDH7A1 gene are associated with pyridoxine-dependent epilepsy.
Other serious disorders associated with lysine metabolism are due to failure of the transport systems for lysine and the other dibasic amino acids across the intestinal wall. Lysine is essential for protein synthesis; and deficiencies of its transport into the body can cause seriously diminished levels of protein synthesis. Probably more significant however, is the fact that arginine is transported on the same dibasic amino acid carrier, and resulting arginine deficiencies limit the quantity of ornithine available for the urea cycle. The result is severe hyperammonemia after a meal rich in protein. The addition of citrulline to the diet prevents the hyperammonemia.
Lysine is also important as a precursor for the synthesis of carnitine, required for the transport of fatty acids into the mitochondria for oxidation. Free lysine does not serve as the precursor for this reaction, rather the modified lysine (6-N-trimethyllysine) found in certain proteins. Some organisms modify lysine within proteins to trimethyllysine using SAM as the methyl donor to transfer methyl groups to the ε-amino of the lysine side chain. Hydrolysis of proteins containing trimethyllysine provides the substrate for the subsequent conversion to carnitine. Once trimethyllysine is released from proteins within the lysosomal compartment, the overall pathway to carnitine synthesis requires four separate reactions. Most human tissues can convert trimethyllysines to γ-butyrobetaine (the compound prior to carnitine) but only the liver, kidney, brain, and testes express the γ-butyrobetaine dioxygenase enzyme (also called γ-butyrobetaine 2-oxoglutarate dioxygenase or γ-butyrobetaine hydroxylase) that hydroxylates γ-butyrobetaine forming carnitine. Although these four tissues can synthesize carnitine, only the liver and the kidneys can transport carnitine to the blood. The gene encoding γ-butyrobetaine dioxygenase is identified as BBOX1.
Synthesis of carnitine. Carnitine is synthesized from the trimethylated lysine released from proteins following their degradation in the lysosome. A series of four reactions convert trimethyllysine to carnitine. The first and last reactions of carnitine synthesis are catalyzed by ascorbate and ferrous (Fe2+) iron-requiring dioxygenases. The first reaction is catalyzed by trimethyllysine hydroxylase, epison (also called trimethyllysine dioxygenase). The second reaction is catalyzed by 3-hydroxytrimethyllysine aldolase. The third reaction is catalyzed by aldehyde dehydrogenase 9 family, member A1 (ALDH9A1). The ALDH9A1 encoded enzyme was formerly known as 4-N-trimethylaminobutyraldehyde dehydrogenase (TMABADH). The last reaction is catalyzed by γ-butyrobetaine dioxygenase (also called γ-butyrobetaine 2-oxoglutarate dioxygenase and γ-butyrobetaine hydroxylase) encoded by the BBOX1 gene.
Histidine catabolism begins with release of the α-amino group catalyzed by histidine ammonia-lyase (also called histidase), introducing a double bond into the molecule. As a result, the deaminated product, urocanate, is not the usual α-keto acid associated with loss of α-amino nitrogens. The histidase enzyme is encoded by the HAL gene located on chromosome 12q22-q24.1 and is composed of 21 exons generating three alternatively spliced mRNAs. The end product of histidine catabolism is glutamate, making histidine one of the glucogenic amino acids.
Another key feature of histidine catabolism is that it serves as a source of ring nitrogen to combine with tetrahydrofolate (THF), producing the 1-carbon THF intermediate known as N5-formimino-THF. The latter reaction is one of two routes to N5-formimino-THF. Urocanate is converted to 4-imidazolone-5-propionate via the action of urocanate hydratase 1 (encoded by the UROC1 gene). The UROC1 gene is located on chromosome 3q21.3 and is composed of 21 exons that generate two alternatively spliced mRNAs. The 4-imidazolone-5-propionate is then converted to N-formimidoyl-L-glutamte via the action of an imidazolone propionase activity. The imidazolone propionase activity is encoded by the amidohydrolase domain-containing 1 gene (symbol: AMDHD1). The AMDHD1 gene is located on chromosome 12q23.1 and is composed of 9 exons that encode a 426 amino acid protein. The enzyme formimidoyltransferase cyclodeaminase (also called glutamate formiminotransferase) then transfers the formimino group from N-formimidoyl-L-glutamte to THF yielding N5-formimino-THF and glutamate. Formimidoyltransferase cyclodeaminase is encode by the FTCD gene located on chromosome 21q22.3 which is composed of 16 exons that generate two alternatively spliced mRNAs, both of which encode the same 541 amino acid protein.
Catabolism of histidine. Histidine catabolism proceeds via a 4-step pathway to glutamate. The process of histidine catabolism represents, not only a catabolic reaction pathway, but a major folic acid derivative biosynthesis pathway. In the course of the catabolism, a portion of the carbon skeleton of histidine is transferred to tetrahydrofolate (THF) forming the folate derivative, N5-formimino-THF.
The principal genetic deficiencies associated with histidine metabolism are associated with mutations in the HAL, UROC1, and FTCD gene. Mutations in the HAL gene result in histidinemia which is relatively benign. The disease, which is of relatively high incidence (1 in 10,000), is most easily detected by the absence of urocanate from skin and sweat, where it is normally found in relative abundance. UROC1 mutations have only been reported in a few individuals who inherited compound heterozygous missense mutations. These individuals exhibited mental retardation, short stature, and episodic aggressiveness and affection-seeking behaviors. Inherited defects in the FTCD gene represent the second most common cause of inborn errors in folate metabolism. Potential for severe mental retardation is the main clinical feature associated with FTCD deficiency. Patients with FTCD defects will also present with megaloblastic anemia due to the role of folate derivatives in the synthesis of purine and thymine nucleotides.
Decarboxylation of histidine in the intestine by bacteria gives rise to histamine. Similarly, histamine is synthesized in numerous tissues by the decarboxylation of histidine catalyzed by histidine decarboxylase which is a pyridoxal phosphate-requiring (B6) enzyme. The histidine decarboxylase gene (symbol: HDC) is located on chromosome 15q21.1 and is composed of 14 exons that encode a protein of 662 amino acids.
Histamine exerts multiple activities but the two most significant are its roles in immunologic response to antigen and inducing the release of hydrogen ion (H+) by parietal cells of the stomach to generate the HCl necessary for gastric digestion. The largest amount of histamine produced in the body is that made by mast cells and basophils. If these cells are sensitized by the presentation of IgE on their surfaces they will degranulate in response to antigen binding, releasing histamine into the circulation. The response to this release is bronchoconstriction and vasodilation which are the general symptoms associated with asthma and various allergic reactions. Within the gastrointestinal system, histamine is produced in the enterochromaffin-like cells of the stomach. When histamine is released from these cells, in response to vagal nerve stimulation, it binds to specific receptors on parietal cells triggering the mobilization of the proton pump of the parietal cell to the apical membrane allowing for increased H+ transport into the lumen of the stomach. All of the actions of histamine are the result of binding to one of four cell surface receptors (H1–H4), all of which are G-protein coupled receptors (GPCRs). The H1 receptor is coupled to a Gq-type G-protein and is responsible for triggering bronchoconstriction and vasodilation. The H2 receptor is a Gs-type G-protein and is present on parietal cells and vascular smooth muscle cells.
Catabolism of tryptophan in humans results in the formation of acetoacetate. The first enzyme of the tryptophan catabolic pathway opens the indole ring. This enzyme is tryptophan 2,3-dioxygenase which is encoded by the TDO2 gene located on chromosome 4q31–q32 and is composed of 12 exons that encode a protein of 406 amino acids. The product of the TDO2 reaction is N-formyl-kynurenine. The TDO2 gene is highly inducible, leading to increasing concentrations of the enzyme, of up to 10-fold, on a diet high in tryptophan. The product of the TDO2 enzyme is the compound kynurenine. Tryptophan catabolism can also be initiated by the enzyme indoleamine 2,3-dioxygenase 1 encoded by the IDO1 gene. The activity of the IDO1 enzyme also results in the generation of N-formyl-kynurenine. The IDO1 gene is located on chromosome 8p12–p11 and is composed of 10 exons that generate a protein of 403 amino acids. N-formyl-kynurenine is then converted to kynurenine by the enzyme, arylformamidase (also called kynurenine formamidase), encoded by the AFMID gene.
Kynurenine is the first key branch point intermediate in the catabolic pathway leading to three distinct catabolic fates for tryptophan. Kynurenine can undergo deamination in a transamination reaction. The transamination reaction can be catalyzed by several different transaminases. One of these enzymes is the human homolog of mouse kynurenine aminotransferase II, yielding kynurenic acid. The human kynurenine aminotransferase II (KAT II, KAT2) enzyme is called aminoadipate aminotransferase which is encoded by the AADAT gene. The enzyme encoded by the AADAT gene has two aminotransferase activities, one of which is utilized in the saccharopine pathway of lysine catabolism, the other is used in the transamination of kynurenine. Another kynurenine transaminase is cysteine conjugate-beta lyase 2 encoded by the CCBL2 gene. The CCBL2 encoded protein was formerly known as kynurenine aminotransferase III (KAT III, KAT3). Another, related enzyme, that was once called kynurenine aminotransferase I (KAT I, KAT1) is cysteine conjugate-beta lyase encoded by the CCBL1 gene. The CCBL1 encoded protein is a cytosolic enzyme that, as its name implies, metabolizes cysteine conjugates.
Kynurenic acid and metabolites have been shown to act as anti-excitotoxics and anti-convulsives. High levels of kynurenic acid have been found in the urine of individuals suffering from schizophrenia. Kynurenic acid has been shown to act as a non-competetive antagonist at the glycine binding site of the NMDA receptor (NMDA = N-methyl-D-aspartate) which is an ionotropic (ligand-gated ion channel) receptor for glutamate. The NMDA receptor is a key component of the glutamatergic neurotransmission system believed to be involved in the pathophysiology of schizophrenia, thus explaining the potential role of kynurenic acid in schizophrenia.
Catabolic pathways for tryptophan. Tryptophan catabolism to acetoacetate also involves functional metabolism to several important bioactive compounds. These compounds include the nicotinamide adenine dinucleotide co-factors, NAD+ and NADP+, kynurenic acid, and quinolinic acid. TDO2: tryptophan 2,3-dioxygenase. IDO1: indoleamine 2,3-dioxygenase 1. AADAT: aminoiadipate aminotransferase. HAAO: 3-hydroxyanthranilate 3,4-dioxygenase. ACMS: α-amino-β-carboxymuconate-ε-semialdehyde.
Kynurenine can also undergo a series of catabolic reactions resulting in complete oxidation to acetoacetyl-CoA or this pathway can also be utilized to allow kynurenine to serve as an important intermediate in the pathway for the synthesis of the nicotinamide adenine dinucleotide co-factors, NAD+ and NADP+. The first reaction in this pathway of kynurenine metabolism is catalyzed by kynurenine hydroxylase (kynurenine 3-monooxygenase) forming 3-hydroxykynurenine. Kynurenine hydroxylase is encoded by the KMO gene located on chromosome 1q42–q44 and is composed of 16 exons that generate a protein of 486 amino acids. The next step in the pathway is catalyzed by kynureninase and produces 3-hydroxyanthranilic acid and the amino acid alanine. It is the production of alanine residues that allows tryptophan to be classified among the glucogenic amino acids. Kynureninase is a pyridoxal phosphate (vitamin B6)-requiring enzyme encoded by the KNYU gene. The KYNU gene is located on chromosome 2q22.2 and is composed of 23 exons that generate several alternatively spliced mRNAs that encode two distinct isoforms of the enzyme. Kynureninase can also act directly on kynurenine to produce anthranilic acid with the release of alanine. The anthranilic acid subsequently is converted to 3-hydroxyanthranilic acid. This latter two-step reaction is a minor component of overall tryptophan catabolism. The next step in the pathway is the conversion of 3-hydroxyanthranilic acid to quinolinic acid catalyzed by the enzyme 3-hydroxyanthranilate 3,4-dioxygenase which is encoded by the HAAO gene. Quinolinic acid is ultimately converted, via several steps, to the nicotinamide adenine dinucleotide co-factors. Quinolinic acid is also an excitatory neurotoxic compound that functions via its ability to activate the glutamate NMDA receptors. An intermediate in the HAAO catalyzed reaction is α-amino-β-carboxymuconate-ε-semialdehyde (ACMS). This intermediate can be metabolized via the action of the enzyme ACMS decarboxylase. This latter reaction is important for the prevention of over accumulation of quinolinic acid from ACMS. The product of the ACMS decarboxylase reaction goes on to be further metabolized to acetoacetyl-CoA, the end product of complete tryptophan catabolism.
Aside from its role as an amino acid in protein biosynthesis, tryptophan also serves as a precursor for the synthesis of the neurotransmitters serotonin and melatonin. These products are discussed in Specialized Products of Amino Acids.back to the top